AZD-103

CNW Group: "Positive Results Released from Canadian Phase I Clinical Trial of AZD-103 showed that AZD-103 has a favourable pharmacokinetic profile and preliminary safety data indicated that AZD-103 was well tolerated and no safety concerns or significant adverse events were observed in the study."